Cocrystal Pharma's CDI-988 Gets IRB Approval for Phase 1b Norovirus Study
ByAinvest
Thursday, Dec 18, 2025 8:09 am ET1min read
COCP--
Cocrystal Pharma has received IRB approval from Emory University School of Medicine to initiate a Phase 1b human challenge study with CDI-988. The study aims to evaluate CDI-988 as both a preventive and treatment for norovirus infections. Screening of study subjects is underway, with enrollment expected to begin in Q1 2026. CDI-988 is the first oral broad-spectrum antiviral drug candidate for norovirus, with no approved treatments or vaccines currently available.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet